Malaysian Genomics partners De Cell to bring cell-gene therapy programme to market


Malaysian Genomics Resource Centre Bhd executive chairman Azri Azerai

KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd's (MGRC) wholly-owned subsidiary MGRC Healthcare Sdn Bhd is collaborating with De Cell Bhd for the commercialisation of the former's cell-gene therapy programme.

In a statement, the genomics and biopharmaceutical specialist said it will provide technical and production support to optimise the operational efficiency and market deployment of the EXOGENETIX programme.

De Cell will take on the role of exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme's market presence and success.

"This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies.

"By combining MGRC Healthcare's production capabilities with De Cell's marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the EXOGENETIX programme," said Malaysian Genomics executive chairman Azri Azerai.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Hume Cement appoints William Tan as group managing director
COP30: TNB a critical enabler to advance regional energy cooperation via Asean power grid
Ringgit ends slightly lower vs greenback on Fed rate outlook caution
Powerwell to expand into East Malaysia via strategic M&A
Bursa Malaysia's key index ends higher near 16-month peak
Velesto unit disposes of entire stake in Velesto Workover for RM16.5mil
Kim Loong anticipates satisfactory FY26 performance
Perdana Petroleum unit receives two work orders from PETRONAS Carigali
Awantec unit bags two contracts to supply AI tools to public unis worth a combined RM16.41mil
Willowglen MSC unit signs remote terminal unit supply contract for RM8.59mil

Others Also Read